Frovatriptan versus other triptans in the acute treatment of migraine: Pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies

Pietro Cortelli, Gianni Allais, Vincenzo Tullo, Chiara Benedetto, Dario Zava, Stefano Omboni, Gennaro Bussone

Research output: Contribution to journalArticle

Abstract

The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-totreat analysis. Rate of PF episodes at 2 h was 30% with F and 34% with comparators (p = NS). PR episodes at 2 h were 55% for F and 59% for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22% F vs. 21% comparators). Rate of recurrence was significantly (p

Original languageEnglish
JournalNeurological Sciences
Volume32
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2011

Fingerprint

Tryptamines
Migraine Disorders
Multicenter Studies
zolmitriptan
Migraine without Aura
Migraine with Aura
Pain
Therapeutics
Cross-Over Studies
Safety
Recurrence
Pain-Free
frovatriptan

Keywords

  • Almotriptan
  • Frovatriptan
  • Migraine
  • Rizatriptan
  • Zolmitriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Frovatriptan versus other triptans in the acute treatment of migraine : Pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. / Cortelli, Pietro; Allais, Gianni; Tullo, Vincenzo; Benedetto, Chiara; Zava, Dario; Omboni, Stefano; Bussone, Gennaro.

In: Neurological Sciences, Vol. 32, No. SUPPL. 1, 05.2011.

Research output: Contribution to journalArticle

Cortelli, Pietro ; Allais, Gianni ; Tullo, Vincenzo ; Benedetto, Chiara ; Zava, Dario ; Omboni, Stefano ; Bussone, Gennaro. / Frovatriptan versus other triptans in the acute treatment of migraine : Pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. In: Neurological Sciences. 2011 ; Vol. 32, No. SUPPL. 1.
@article{c427966a4b5f4abe8f426f47aacf5d4b,
title = "Frovatriptan versus other triptans in the acute treatment of migraine: Pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies",
abstract = "The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-totreat analysis. Rate of PF episodes at 2 h was 30{\%} with F and 34{\%} with comparators (p = NS). PR episodes at 2 h were 55{\%} for F and 59{\%} for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22{\%} F vs. 21{\%} comparators). Rate of recurrence was significantly (p",
keywords = "Almotriptan, Frovatriptan, Migraine, Rizatriptan, Zolmitriptan",
author = "Pietro Cortelli and Gianni Allais and Vincenzo Tullo and Chiara Benedetto and Dario Zava and Stefano Omboni and Gennaro Bussone",
year = "2011",
month = "5",
doi = "10.1007/s10072-011-0551-2",
language = "English",
volume = "32",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Frovatriptan versus other triptans in the acute treatment of migraine

T2 - Pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies

AU - Cortelli, Pietro

AU - Allais, Gianni

AU - Tullo, Vincenzo

AU - Benedetto, Chiara

AU - Zava, Dario

AU - Omboni, Stefano

AU - Bussone, Gennaro

PY - 2011/5

Y1 - 2011/5

N2 - The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-totreat analysis. Rate of PF episodes at 2 h was 30% with F and 34% with comparators (p = NS). PR episodes at 2 h were 55% for F and 59% for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22% F vs. 21% comparators). Rate of recurrence was significantly (p

AB - The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-totreat analysis. Rate of PF episodes at 2 h was 30% with F and 34% with comparators (p = NS). PR episodes at 2 h were 55% for F and 59% for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22% F vs. 21% comparators). Rate of recurrence was significantly (p

KW - Almotriptan

KW - Frovatriptan

KW - Migraine

KW - Rizatriptan

KW - Zolmitriptan

UR - http://www.scopus.com/inward/record.url?scp=79960145588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960145588&partnerID=8YFLogxK

U2 - 10.1007/s10072-011-0551-2

DO - 10.1007/s10072-011-0551-2

M3 - Article

C2 - 21533722

AN - SCOPUS:79960145588

VL - 32

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 1

ER -